Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. (2nd June 2020)

• Record Type: Journal Article
• Authors: Baloche, Valentin; Ferrand, François-Régis; Makowska, Anna; Even, Caroline; Kontny, Udo; Busson, Pierre
• Is Part Of: Expert opinion on therapeutic targets. Volume 24:Number 6(2020:Jun.)
• Page Start: 545
• Page End: 558
• Publication Date: 2020-06-02
• Subjects: Nasopharyngeal carcinomas -- cdk4/6 inhibitors -- latent EBV-infection -- EBNA1; LMP1/LMP2 -- immune checkpoint inhibitors -- galectin-9 -- interferon-β -- NK cells -- Head and Neck carcinomas; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2020.1751820
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Nasopharyngeal carcinoma (NPC) is a major public health problem in several countries, especially those in Southeast Asia and North Africa. In its typical poorly differentiated form, the Epstein-Barr virus (EBV) genome is present in the nuclei of all malignant cells with restricted expression of a few viral genes. The malignant phenotype of NPC cells results from the influence of these viral products in combination with cellular genetic, epigenetic and functional alterations. With regard to host/tumor interactions, NPC is a remarkable example of immune escape in the context of a hot tumor. Areas covered : This article has an emphasis on emerging therapeutic targets that are considered upstream or at an early stage of clinical application. It examines targets related to cellular oncogenic alterations, latent EBV infection and tumor interactions with the immune system. Expert opinion : There is a remarkable emergence of new agents that target EBV products. The clinical application of these agents would benefit from a systematic and comprehensive molecular classification of NPCs and from easy access to pre-clinical models in public repositories. There is a strong rationale for more investigations on the potential of immune modulators, especially those related to NK cells.